In 2022, Oladejo et al. reported that a Listeria-based vaccine encoding an antigenic fragment of CD105 (Lm-LLO-CD105A) showed promising therapeutic efficacy in RCC by targeting both tumor cells and tumor-associated vasculature. This evidence concerns the gene ENG and neoplasm.